As part of the 2018 Laboratory Design Conference agenda, the Novartis-Penn Center for Advanced Cellular Therapies (CACT) will open its doors for attendees to explore this innovative facility.

Located at in the Penn Medicine campus in Philadelphia, this award-winning project has made national headlines for the ground-breaking Chimeric Antigen Receptor (CAR) research, which enables a patient’s own immune cells to be reprogrammed outside of their body and re-infused to “hunt” for and potentially destroy tumors.

The strategic layout and organization of the laboratory environments will ultimately reduce the time it takes to create the “hunter cells” for one patient by 50 percent. At the outset of this effort, it took an entire month to tackle this for each patient; now, it only takes two weeks.

Launching a Mission to Defeat Cancer VP Joe Biden Visits Penn Medicine CACT

Novartis-Penn CACT Featured in Science Magazine

Novartis-Penn CACT featured in STAT

Sign up for the tour today as space is limited >